This is an aggregated industry headline. Read the full story at FiercePharma →
Lonza expands partnership with US drugmaker, boosts capacity for ADCs
Contract manufacturing powerhouse Lonza is growing in more ways than one. The Swiss company revealed this week that it is expanding its capacity to manufacture antibody-drug conjugates-and that it has increased the scope of its partnership with a large, unnamed U.S. drugmaker.
By FiercePharma
· Jul 5, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
United Therapeutics has paid $140 million to buy Thymmune Therapeutics for preclinical regenerative cell thera…
The WeekBriefing
China’s approval of a CAR‑T for solid tumors breaks a scientific barrier and raises pressure on U.S. developer…
The WeekFiercePharma ↗
Nominate up-and-coming early-career pharma marketing pros here to be featured in Fierce's "Rising Stars" Q&…